Fezolinetant

DB15669ApprovedInvestigationalSmall moleculeNeurokinin 3 Receptor Antagonist

Fezolinetant is a non-hormonal drug used to treat moderate to severe vasomotor symptoms due to menopause. Vasomotor symptoms (VMS), more colloquially known as hot flashes or night sweats, are some of the most common symptoms in menopause.

Chemical structure of Fezolinetant
Mechanism
Curator reviewed · 1 reference
Primary indication
Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.Curator reviewed · 1 structured indication
Formula / weight
C16H15FN6OS · 358.4 g/mol (avg)
First approval
Canada, 2024 · United States, 2023 · European Union, 2024
Code names
ESN-364
Brand names
  • Veoza
  • Veozah

Resolves to

Compound
UNII83VNE45KXXCAS1629229-37-3ChEMBLCHEMBL3608680ChEBI229236PubChem117604931
Clinical / RWD
RxNorm2637134ATCG02CX06
Structure
InChIKeyPPSNFPASKFYPMN-SECBINFHSA-NSMILESC[C@H]1N(CCN2C1=NN=C2C1=NC(C)=NS1)C(=O)C1=CC=C(F)C=C1
Targets
P29371TACR3

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
333Drug interactionsStructured to mechanism, not free text
Sign in
20Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
6ContraindicationsEach with its own population and attribute set
Sign in
11Marketed productsAcross 4 countries and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 9 drug categories
Sign in
17+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Fezolinetant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In